MC2 Therapeutics Announces Positive Top-line Results from Phase 3 Clinical Trial Comparing MC2-01 Cream to Taclonex® in Adults with Psoriasis
MC2 Therapeutics A/S, an emerging pharmaceutical company developing next generation patient-friendly topical therapies for skin and eye diseases, today announced the following top-line data from its US Phase 3 study (n=796) on the company’s investigational drug, MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%):
- MC2-01 Cream is superior to Taclonex® Topical Suspension (“Taclonex®”) at Week 8 based on treatment success defined as a minimum two-point decrease in the Physician Global Assessment (PGA) score (40.1% versus 24.0%, p < 0.0001). Accordingly, the trial met its primary endpoint to demonstrate non-inferiority of MC2-01 Cream to Taclonex®.
- MC2-01 Cream is superior to Taclonex® based on percentage reduction in mPASI from baseline to Week 8 (64.8% versus 52.3%, p < 0.0001) (MC2-01 Cream demonstrated fast onset of action with superiority (p < 0.009) to Taclonex® already at Week 1).
- MC2-01 Cream is superior to Taclonex® in Patient Treatment Convenience (p < 0.0001)
- MC2-01 Cream provides a robust reduction in itch (60.2% at Week 4) measured by the frequency of a four-grade or greater improvement on an 11-point numeric rating scale of itch severity.
“The significant improvements in both treatment success and patient reported treatment convenience are particularly encouraging,” said Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, and lead investigator in the study. “Enhanced patient satisfaction enabled by the MC2-01 Cream PAD™ formulation may increase treatment compliance among patients, and positively impact real-life treatment outcomes even further. As such PAD™ Technology holds the promise of redefining topicals.”
The adverse events seen in the trial were predictable pharmacological class effects typically associated with calcipotriene and topical corticosteroids, and the safety profile of MC2-01 cream was similar to that known from Taclonex®.
MC2 Therapeutics is pursuing a patient-centric approach to treating psoriasis by developing a once-daily, non-greasy topical treatment that can be conveniently applied to a large surface area of the body and absorbs quickly into the skin to provide rapid symptom relief. MC2-01 Cream is designed to allow patients to comfortably wear clothes immediately after application and go about their daily routines.
“We are extremely pleased with these superiority data from the head-to-head study of MC2-01 Cream versus Taclonex®, which is widely regarded as a first line topical treatment of psoriasis,” stated Jesper J. Lange, President of MC2 Therapeutics. “Psoriasis is a life-long condition that significantly impacts patients’
quality of life. MC2-01 Cream is designed to provide patients a new standard of care for the topical treatment of psoriasis that helps them effectively and conveniently manage their condition and minimize disruption to their daily routine and social interactions.”
Lange added, “These data confirm the tremendous potential for PAD™ Technology as a broad platform for the development of new topical drugs that releases the full potential of the active ingredients, while being very pleasant to use for patients in daily routines. PAD™ Technology enables an expanded formulation space that opens the door for an array of new topical therapies that might not otherwise be developed e.g. due to challenges with delivery, solubility and stability of active ingredients.”
About the MC2-01 Phase 3 Trial
This Phase 3, randomized, multicenter, investigator-blind, parallel-group trial evaluated the efficacy and safety of MC2-01 Cream compared to MC2-01 vehicle and the active comparator (Taclonex®) in subjects with psoriasis vulgaris. The trial enrolled 796 patients at 55 dermatologists across the United States. Subjects applied trial medication topically once daily for eight weeks.
The primary objective was to show therapeutic non-inferiority of MC2-01 Cream to the active comparator, as well as to characterize the safety profile of MC2-01 Cream in subjects with psoriasis vulgaris. The primary efficacy endpoint was the proportion of subjects in each treatment group with “treatment success” at week eight, defined as a minimum two-point decrease from baseline in PGA score (i.e., a score of 0 (clear) or 1 (almost clear) disease for subjects with moderate disease at baseline, or a score of 0 (absent) for subjects with mild disease at baseline).
The full data from the trial will be presented at upcoming medical conferences. Global development of MC2- 01 will continue and MC2 Therapeutics plans to submit a New Drug Application (NDA) to FDA in the first half of 2019.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held pharmaceutical company that is applying its proprietary PAD™ Technology as a broad platform to enable the development of a new generation of patient friendly topical prescriptions and consumer healthcare products. The Company is advancing its own portfolio of products to treat skin and eye conditions and is collaborating with other pharmaceutical companies to unlock the full potential of their active pharmaceutical ingredients in new topical drug candidates.
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com
MC2 Therapeutics A/S
Jesper J. Lange, +45 2018 2222
Mette Thorn Sorensen, +45 4138 4300
James Heins, +1 203-682-8512
Darcie Robinson, +1 203-682-8379
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IFF Announces Pricing of $1,500,000,000 Senior Notes Offering24.9.2018 22:25 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensorial experiences that move the world, today announced that it has priced its public offering of $300,000,000 aggregate principal amount of its 3.400% senior notes due 2020, $400,000,000 aggregate principal amount of its 4.450% senior notes due 2028 and $800,000,000 aggregate principal amount of its 5.000% senior notes due 2048. IFF intends to use the net proceeds from the offering to pay a portion of the consideration for the previously announced merger with Frutarom Industries Ltd. and to pay related fees and expenses. IFF anticipates that the offering will close on September 26, 2018, subject to customary closing conditions. The offering is not contingent upon the consummation of the merger. If the closing of the merger has not occurred on or prior to February 7, 2019, or, if prior to such date, the merger agreement with Frutarom is terminated, IFF will be required t
Iberdrola Recognized as United Nations Global Compact LEAD24.9.2018 21:12 | Pressemelding
Today, Iberdrola, one of the world’s largest utilities and the leading renewable energy producer, is pleased to announce that the Company has been recognized as Global Compact LEAD for demonstrating its ongoing commitment to the United Nations Global Compact and its Ten Principles for responsible business. Announced at UN Headquarters in New York during the UN Global Compact Leaders Summit 2018, Iberdrola was identified as being among the highest-engaged participants of the world’s largest corporate sustainability initiative. Lise Kingo, CEO and Executive Director of the UN Global Compact, said, “LEAD companies represent the highest level of engagement with the UN Global Compact. Achieving the Sustainable Development Goals and creating the world we want will not happen without bold action from the responsible business community. We need companies of all sizes — like the ones recognized today — to improve their performance, no matter where they are on their sustainability journey.” “Sin
Pre-Registration for MapleStory 2 Starts Today24.9.2018 17:00 | Pressemelding
Pre-registration for MapleStory 2, the newest MMORPG adventure in Maple World, is available starting today. From September 24 through October 8, players can sign-up on the MapleStory 2 Pre-Registration site available here and earn exclusive rewards! Pre-registration web rewards will include unique in-game items such as the Roosting Seagull, Rustic Mushcabin Name Tag, and the Dusty Rickshaw. From September 24 through October 8, players can also receive a Mint Body Pillow by retweeting the new Runeblade trailer on Twitter and/or liking on Facebook. In addition to pre-registration, players who purchased a Founder’s Pack can jump into Head Start starting October 1, which will allow them to join MapleStory 2 's vibrant and immersive world ahead of global launch on October 10. Along with beta improvements, Head Start (October 1 - October 10) will include: Character progression that carries over to the official launch 6 character slots Founder’s Pack items Access to Gemstones Lv. 1 - 50 Quest
First Engineering Faculty in Canada Named after a Woman: Business Leader Gina Cody Makes Historic $15 Million Donation to Montreal’s Concordia University24.9.2018 15:15 | Pressemelding
Three decades after becoming the first woman to earn a PhD in building engineering from Concordia University, Gina Parvaneh Cody, MEng 81, PhD 89, has made history by giving $15 million to her alma mater. In recognition of her transformative gift to the “Campaign for Concordia: Next-Gen. Now”, the university has named its faculty of engineering and computer science after the alumna. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005425/en/ (Photo: Business Wire) The Gina Cody School of Engineering and Computer Science is the first engineering faculty in Canada — and one of the first internationally — to be named after a woman. Gina Cody, a top business leader and building engineer, credits much of her success to Concordia because the university provided her with an entrance scholarship. “I arrived in Canada as a young student from Iran in 1979 with $2,000,” she says. “Concordia welcomed me and provided me with support
Dole’s Standard Fruit Celebrates 20-Year Milestone as Environmental Leader24.9.2018 15:00 | Pressemelding
Earlier in September Dole Food Company participated in a celebration of the twentieth anniversary of the company’s initial receipt of its ISO 14001 Certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005079/en/ Dole Fresh Fruit President Renato Acuña speaks at the anniversary celebration of Dole's landmark environmental sustainability certification. (Photo: Business Wire) On July 2, 1998, Standard Fruit Company of Costa Rica S.A., a subsidiary of Dole Food Company, Inc., became the first agricultural and banana company in the world to receive the globally recognized ISO 14001 Certification for its environmental management policy and the establishment of its Integrated Management System. With the certification, the company further strengthened its robust Environmental Management System, with results that place it at the forefront in the sustainable production of bananas and pineapples. The celebration event, h
Helsinki Joins New York in Commitment to Review Local Progress Toward Global Sustainable Development Goals24.9.2018 14:42 | Pressemelding
In July 2018, the City of New York became the first city in the world to submit to the United Nations its progress toward the Sustainable Development Goals (SDG’s) on city level. As the first European city Helsinki will follow New York City and become the second city in the world in effort to showcase crucial role of cities in achieving UN agenda for people, prosperity and planet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005633/en/ As the first European city Helsinki will follow New York City and become the second city in the world in effort to showcase crucial role of cities in achieving UN agenda for people, prosperity and planet. Photo: Jussi Hellsten The Mayor of Helsinki Jan Vapaavuori announced Helsinki’s commitment to the voluntary local review at a panel conversation with New York City’s Commissioner of International Affairs Penny Abeywardena at the Social Good Summit in New York City on Sunday. Even thou